a voltage-gated potassium channel subunit, K v 7.2, leads to refractory seizures and a grossly abnormal EEG exhibiting multifocal epileptiform discharges or a burst suppression pattern. Although roughly two-thirds of patients can achieve seizure freedom some months to years after onset, they are developmentally delayed, with intellectual disabilities ranging from mild to profound, and have axial hypotonia, limb spasticity, and impaired visual tracking.
of all epilepsies. [3] [4] [5] The ultimate goal of human genetics research is to aid the development of disease-targeted treatment. Is this achievable in the field of epilepsy? We have known since the early 1930s that genetics play an important role in epilepsy. However, epilepsies are known to be genetically complex disorders for most patients, and not until the past decade have advances been made to unravel the genetics. This review discusses recent progress in epilepsy genetics, and Table 1 summarizes the main syndromes and associated genes, including some additional syndromes otherwise beyond the scope of this text. We highlight the mechanistic insights gained by identification of epilepsy genes and discuss how a genetic diagnosis can influence patient treatment.
Monogenic epilepsies are interesting symptomatic epilepsies, with more than 300 genetic disorders described to date. These include ion and non-ion channel disorders in familial cases. These disorders started with the discovery of the first epilepsy gene, CHRNA4, in 1995. 6 At that time, genetic discoveries were mostly restricted to large families having milder, inherited epilepsies using linkage analysis. This technique led to the discovery of the genes behind autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 6 and genetic/generalized epilepsy with febrile seizures plus (GEFS+). 7 However, linkage analysis is not sufficient to uncover de novo mutations responsible for severe epileptic encephalopathies. More recently, candidate gene screening, microarray techniques, and massive parallel sequencing technology have been responsible for accelerated discovery of epilepsy genes. 8, 9 Gene discovery has reinforced the complex nature of genetics in disease. A given genotype may be expressed as a range of phenotypes and severities.
For example, a missense mutation in the SCN1A gene may result in the milder GEFS+ phenotype, 7,10-12 whereas a loss of function mutation may result in severe myoclonic epilepsy of infancy (SMEI)/Dravet syndrome (DS). [13] [14] [15] formation, which may also account for findings of developmental delay with severe to profound intellectual disability, hypotonia, and absence of speech in the five patients who had the mutation. 9 Overall, patients who had epileptic encephalopathies were found to carry more de novo mutations than controls.
9
A recent study showed that 1 % of patients having epileptic encephalopathy and no previous genetic diagnosis were discovered to carry a mutation for SCN8A, which encodes Na v 1. The progressive myoclonic epilepsies (PMEs) are characterized by myoclonus, tonic-clonic seizures, ataxia, and progressive neurologic decline. Additionally, patients having CNV with epilepsy are more likely to have developmental delay, intellectual disability, or autism spectrum disorder. 35 In addition, CNVs are responsible for 3 % of genetic/idiopathic generalized epilepsies (GGEs): Deletions at 15q13.3, 15q11.2, and 16p13.11 each account for 1 % of GGEs. 35, 36 Although germline mutations may account for a large percent of epilepsy With the emerging picture of complexity in epilepsy and genetics, the clinician may be inclined to abandon gene testing altogether. However, some conditions warrant consideration of genetic diagnosis, for it may influence treatment. Diagnosis of BNFE may influence a decision to defer treatment. Genetic testing can identify inborn errors of metabolism such as GLUT1 deficiency and pyridoxine-dependent epilepsy when successful therapy hinges on specific nutritional approaches (ketogenic diet and pyridoxine supplementation, respectively). 5, [40] [41] [42] Sodium channel blockers may exacerbate seizures in patients who have GEFS+ and DS. 43 More challenging, advances in genetics may illustrate the molecular basis for pharmacoresistance to specific medications in some patients and may help predict more effective alternatives. They may also help identify individuals at higher risk for sudden unexplained death in epilepsy (SUDEP): KCNQ1, in addition to encoding a voltage-gated potassium channel expressed in brain, also encodes a cardiac potassium channel that is the most common cause for longed QT syndrome. 44 It is likely that the next 5 years will see major developments in gene sequencing and analytics. The availability of inexpensive whole genome analysis in epilepsy will significantly affect diagnosis and management.
The time is soon arriving for idiopathic epilepsy to disappear from our lexicon and for precision genetic diagnosis and therapeutics to replace uncertainty and tribulations. n
